- •Hormonal replacement treatment (HRT) appears safe in BRCA carriers under 45 years old.
- •HRT was associated with a tripled breast cancer risk for BRCA carriers over 45 years.
- •HRT did not affect age at breast cancer diagnosis and time from oophorectomy till diagnosis.
BRCA1/BRCA2 mutation carriers often undergo risk-reducing salpingo-oophorectomy (RRSO) before natural menopause, raising the issue of hormonal replacement treatment (HRT) use. There is conflicting evidence on the effect of HRT on breast cancer (BC) risk, and there are limited data on risk based on age at exposure. In the general population, HRT users have an increased BC risk (hazard ratio = 1.34). We assessed the impact of short-term HRT use on BC risk among healthy BRCA1/2 mutation carriers, with emphasis on age at exposure to HRT.
A retrospective cohort of 306 consecutive healthy BRCA1/2 mutation carriers who had undergone RRSO was followed up for a mean of 7.26 years. We compared BC incidence over time in carriers who received HRT with that in those who did not receive.
Thirty-six of the carriers were diagnosed with BC, 20 of 148 patients (13.5%) in the HRT group compared with 16 of 155 (10.3%) in the non-HRT group (odds ratio [OR] = 1.4, 95% confidence interval [CI] = 0.7–2.7). In women who were aged 45 years or younger at RRSO, HRT did not affect BC rates. However, in those older than 45 years at RRSO, BC rates were significantly higher in HRT users than in non-users (OR = 3.43, p < 0.05, 95% CI = 1.2–9.8).
In BRCA1/BRCA2 carriers in this study, short-term post-RRSO HRT use was associated with a threefold risk of BC in carriers older than 45 years. These results suggest that risk may be related to time of exposure to HRT around the natural age of menopause, even among BRCA1/2 carriers. Further studies are needed for validation and to guide future recommendations.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Population screening for inherited predisposition to breast and ovarian cancer.Annu Rev Genom Hum Genet. 2020; 21https://doi.org/10.1146/annurev-genom-083118-015253
- The BRCA tumor suppressor network in chromosome damage repair by homologous recombination.Annu Rev Biochem. 2019; 88: 221-245https://doi.org/10.1146/annurev-biochem-013118-111058
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.Nat Med. 2017; 23: 517-525https://doi.org/10.1038/nm.4292
- Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.Am J Hum Genet. 1997; 60: 1059-1067
- Ashkenazi Jewish population frequencies for common mutations in BRCA 1 and BRCA2.Nat Med. 1996; 2: 534-539
- Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.JAMA, J Am Med Assoc. 2017; 317: 2402-2416https://doi.org/10.1001/jama.2017.7112
- Cancer risks among BRCA1 and BRCA2 mutation carriers.Br J Canc. 2007; 96: 11-15https://doi.org/10.1038/sj.bjc.6603535
- Clinical practice guidelines Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention clinical practice guidelines.Ann Oncol. 2016; 27https://doi.org/10.1093/annonc/mdw327
- Meta-analysis of risk reduction estimates associated with risk-reducing salpingo- oophorectomy in BRCA1 or BRCA2 mutation carriers.JNCI J Natl Cancer Inst. 2009; 101https://doi.org/10.1093/jnci/djn442
- Two decades after BRCA: setting care and prevention.2014: 1466-1471https://doi.org/10.1126/science.1251827 (March)
- Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation Carriers: revisiting the evidence for risk reduction.JNCI J Natl Cancer Inst. 2015; 107: 1-9https://doi.org/10.1093/jnci/djv033
- Genetic/familial high-risk Assessment : breast and ovarian.2019
- Long-term health consequences of premature or early menopause and considerations for management.. 2016; 18: 483-491https://doi.org/10.3109/13697137.2015.1020484.Long-term
- The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.J Clin Oncol. 2006; 24: 3576-3582https://doi.org/10.1200/JCO.2005.05.1896
- Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study.Breast Canc Res Treat. 2016; 155: 365-373https://doi.org/10.1007/s10549-016-3685-3
- Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US preventive services task force.JAMA. 2017; 318: 2234-2249https://doi.org/10.1001/jama.2017.16952
- Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.Breast Canc Res Treat. 2008; 107: 103-111https://doi.org/10.1007/s10549-007-9523-x
- Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.J Clin Oncol. 2005; 23: 7804-7810https://doi.org/10.1200/JCO.2004.00.8151
- Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.J Natl Cancer Inst. 2008; 100: 1361-1367https://doi.org/10.1093/jnci/djn313
- Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?No Title.J Clin Oncol. 2011; 29 (1501-1501)
- Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers.JAMA Oncol. 2018; 4: 1059-1065https://doi.org/10.1001/jamaoncol.2018.0211
- The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review.BMC Wom Health. 2017; 17: 1-13https://doi.org/10.1186/s12905-017-0370-6
- Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.Gynecol Oncol. 2019; 153: 192-200https://doi.org/10.1016/j.ygyno.2018.12.014
- Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis.Crit Rev Oncol Hematol. 2018; 132: 111-115https://doi.org/10.1016/j.critrevonc.2018.09.018
- Society at a glance 2014 highlights: Israel, OECD.2014: 1-4 (March)
- The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation.Oncotarget. 2017; 8: 9144-9154https://doi.org/10.18632/oncotarget.13423
- Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.J Natl Cancer Inst. 2014; 106https://doi.org/10.1093/jnci/dju091
- Pregnancies, breast-feeding, and breast cancer risk in the international BRCA1/2 carrier cohort study (IBCCS).J Natl Cancer Inst. 2006; 98: 535-544https://doi.org/10.1093/jnci/djj132
- Presymptomatic awareness of germline pathogenic BRCA variants and associated outcomes in women with breast cancer.JAMA Oncol. 2020; 6: 1460-1463https://doi.org/10.1001/jamaoncol.2020.2059
Published online: March 17, 2021
Accepted: February 2, 2021
Received in revised form: January 28, 2021
Received: December 3, 2020
© 2021 Elsevier Ltd. All rights reserved.